A Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Icotinib Hydrochloride Cream in Healthy Adult Participants, Followed by Patients With Mild to Moderate Psoriasis
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Icotinib (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd
- 12 Jul 2017 Status changed from recruiting to completed.
- 06 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
- 06 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.